CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 289 enrolled
Drug / intervention
Indicorother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03430102
NCT03430102N/ACompleted

Validation of the Indicor Device in Identifying Elevated Left Ventricular End Diastolic Pressure LVEDP

Vixiar Medical, Inc.·observational·Posted Feb 12, 2018·Updated Jun 17, 2020

In Brief

An observational study evaluating Indicor for Heart Failure. Completed, enrolled 289 participants across 4 sites.

Detailed Summary

The study is designed to repeat an initial training set study conducted at Johns Hopkins Medical Center, comparing a new investigational device, Indicor, a non-invasive tool for estimating left ventricular end diastolic pressure (LVEDP), to the gold standard, invasively measured LVEDP via direct measurement via left heart catheterization. The study is divided into an initial training set, followed by the validation set which is designed to support an FDA 510(k) submission and validate the final algorithm. Patients will be enrolled who are scheduled to undergo a cardiac catheterization and will be asked to perform three tests with the Indicor.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedFeb 12, 2018
Enrollment StartFeb 14, 2018
Primary CompletionMar 12, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.4 years ago

Interventions

Indicorother

Calculation of LVEDP via analysis of PPG waveform with Valsalva